%0 Journal Article %T Mitochondrial DNA Copy Number Variations and Serum Pepsinogen Levels for Risk Assessment in Gastric Cancer %+ Institut Pasteur d'Iran %+ Pathogenèse de Helicobacter / Helicobacter Pathogenesis %+ Tehran University of Medical Sciences (TUMS) %+ Academic Center for Education, Culture and Research (ACECR) %A Alikhani, Mehdi %A Saberi, Samaneh %A Esmaeili, Maryam %A Michel, Valérie %A Tashakoripour, Mohammad %A Abdirad, Afshin %A Aghakhani, Arezoo %A Eybpoosh, Sana %A Vosough, Massoud %A Mohagheghi, Mohammad Ali %A Eshagh Hosseini, Mahmoud %A Touati, Eliette %A Mohammadi, Marjan %Z This project was supported by an ACIP (Pasteur International Concerted Action) grant (ACIP2015-10) from Institut Pasteur Paris; and Grant #833 from Pasteur Institute of Iran, as partial fulfillment of MA Ph.D. dissertation (code: TP-9347). %< avec comité de lecture %@ 1028-852X %J Iranian Biomedical Journal %I Pasteur Institute of Iran %V 25 %N 5 %P 323-33 %8 2021-08-22 %D 2021 %R 10.52547/ibj.25.5.323 %M 34425651 %K gastric cancer %K Helicobacter pylori %K mitochondrial DNA copy number %K serum pepsinogen %K Biomarkers %K DNA copy number variation %K Mitochondrial DNA %K Stomach neoplasms %Z Life Sciences [q-bio]/CancerJournal articles %X Background: Variations in mtDNA-CN of PBLs, as a potential biomarker for GC screening has currently been subject to controversy. Herein, we have assessed its efficiency in GC screening, in parallel and in combination with sPG I/II ratio, as an established indicator of gastric atrophy. Methods: The study population included GC (n = 53) and non-GC (n = 207) dyspeptic patients. The non-GC group was histologically categorized into CG (n = 104) and NM (n = 103) subgroups. The MtDNA-CN of PBLs was measured by quantitative real-time PCR. The sPG I and II levels and anti-H. pylori serum IgG were measured by ELISA. Results: The mtDNA-CN was found significantly higher in GC vs. non-GC (OR = 3.0; 95% CI = 1.4, 6.4) subjects. Conversely, GC patients had significantly lower sPG I/II ratio than the non-GC (OR = 3.2; CI = 1.4, 7.2) subjects. The combination of these two biomarkers yielded a dramatic amplification of the odds of GC risk in double-positive (high mtDNA-CN-low sPGI/II) subjects, in reference to double-negatives (low mtDNA-CN-high sPGI/II), when assessed against non-GC (OR = 27.1; CI = 5.0, 147.3), CG (OR = 13.1; CI = 2.4, 72.6), or NM (OR = 49.5; CI = 7.9, 311.6) groups. Conclusion: The combination of these two biomarkers, namely mtDNA-CN in PBLs and serum PG I/II ratio, drastically enhanced the efficiency of GC risk assessment, which calls for further validations. %G English %2 https://pasteur.hal.science/pasteur-03688632/document %2 https://pasteur.hal.science/pasteur-03688632/file/2021-Alikhani%20et%20al.pdf %L pasteur-03688632 %U https://pasteur.hal.science/pasteur-03688632 %~ PASTEUR %~ RIIP %~ CNRS %~ RIIP_IRAN %~ UNIV-PARIS %~ UNIVERSITE-PARIS %~ TEST3-HALCNRS